22:21 , Aug 30, 2018 |  BC Extra  |  Company News

Management tracks: Lilly, Kiadis

Eli Lilly and Co. (NYSE:LLY) said SVP and President of Lilly Oncology Sue Mahony will retire, effective Aug. 31. She is succeeded by Anne White, who is VP of portfolio management and Lilly's Chorus R&D...
18:06 , Jun 29, 2018 |  BC Week In Review  |  Company News

Renal plays Akebia, Keryx merging

Akebia Therapeutics Inc. (NASDAQ:AKBA) will merge with Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) in an all-stock deal, forming a combined company with one chronic kidney disease compound on the market and another in Phase III testing. Keryx shareholders...
22:09 , Jun 28, 2018 |  BC Extra  |  Company News

Renal plays Akebia, Keryx merging

Akebia Therapeutics Inc. (NASDAQ:AKBA) will merge with Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) in an all-stock deal, forming a combined company with one chronic kidney disease compound on the market and another in Phase III testing. The...
17:58 , Mar 30, 2018 |  BC Week In Review  |  Financial News

Akebia raises $89.3M in follow-on

Kidney disease company Akebia Therapeutics Inc. (NASDAQ:AKBA) raised $89.3 million on March 23 through the sale of 8.5 million shares at $10.50 in a follow-on underwritten by Morgan Stanley. The price is a 10% discount...
16:24 , Mar 23, 2018 |  BC Extra  |  Financial News

Akebia raises $89.3M in follow-on

Akebia Therapeutics Inc. (NASDAQ:AKBA) raised $89.3 million through the sale of 8.5 million shares at $10.50 in a follow-on underwritten by Morgan Stanley. The price is a 10% discount to Akebia's close of $11.68 on...
20:17 , Jan 26, 2018 |  BC Week In Review  |  Clinical News

Akebia's vadadustat meets in Phase II dialysis-dependent CKD

Akebia Therapeutics Inc. (NASDAQ:AKBA) reported top-line data from a double-blind, Japanese Phase II study in 60 patients with anemia associated with dialysis-dependent chronic kidney disease (CKD) showing that 150, 300 and 600 mg doses of...
20:46 , Nov 10, 2017 |  BC Week In Review  |  Financial News

Invirsa raises $520K in seed round

Infectious disease play Invirsa Inc. (Columbus, Ohio) raised $520,000 in a seed financing led by CincyTech. Initial investor Rev1 Ventures also participated. Invirsa's lead candidate, INV-102, is in preclinical testing to treat acute conjunctivitis and upper...
00:30 , Oct 20, 2017 |  BC Week In Review  |  Clinical News

Akebia's vadadustat meets in Phase II for non-dialysis-dependent CKD

Akebia Therapeutics Inc. (NASDAQ:AKBA) said oral vadadustat met the primary endpoint of improving mean hemoglobin levels in a Phase II trial to treat anemia in non-dialysis-dependent patients with chronic kidney disease (CKD). Top-line data from...
22:43 , Jul 7, 2017 |  BioCentury  |  Finance

Generalists needed

Following a nearly two-year political overhang on the biotech sector, buysiders believe sentiment once again may be turning positive and starting to catch up with the industry’s positive fundamentals. As evidence, they point to the continued...
20:22 , Jul 7, 2017 |  BC Week In Review  |  Financial News

Akebia raises $58M in follow-on

On June 28, kidney disease company Akebia Therapeutics Inc. (NASDAQ:AKBA) raised $58 million through the sale of 4 million shares at $14.50 in a follow-on underwritten by Morgan Stanley, JMP Securities, Needham, Raymond James, BTIG...